Pharmacological Therapy of Differentiated Thyroid Cancer

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorFrenkel, Yulia
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptKenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.date.accessioned2019-09-24T10:27:34Z
dc.date.available2019-09-24T10:27:34Z
dc.date.created2018
dc.description.abstractThe Thyroid is a magnificent endocrinal organ that have an effect on the whole body. Thyroid cancer is not as common as other solid tumors are, but in its aggressive and metastatic form is very devastating and difficult to treat. Differentiated thyroid cancer can be divided by histological means into papillary and follicular thyroid carcinomas, which are both derived from follicular cells of the thyroid. Usually the treatment solutions are very simple for non-complicated low grade differentiated thyroid cancer, which almost exclusively resolved by surgery and radioactive iodine (RAI). However, in advanced cases this treatment almost always ineffective. Here, the pharmacological research comes into picture. The knowledge of thyroid physiology and genetic background of the disease is essential for mechanisms understanding on which future therapeutic approaches developed on. Although now days differentiated and dedifferentiated thyroid cancer pharmacological treatment approaches are only at the beginning of the way, it has a great potential in not only improving prognosis and survival rate, but also more importantly may be able to improve life quality. This thesis will present current conventional therapeutic protocols such as surgery, TSH suppression and RAI, conventional cytotoxic and external beam radiation therapy as well as a glimpse into the future of advanced and resistant to conventional therapy dedifferentiated thyroid cancer as tyrosine kinase inhibitors, agents act on Ras pathway, MAPK pathway, monoclonal antibodies etc.hu_HU
dc.description.correctorLB
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent81hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/273676
dc.language.isoenhu_HU
dc.subjectthyroidhu_HU
dc.subjectfollicularhu_HU
dc.subjectpapillaryhu_HU
dc.subjectdifferentiated thyroid carcinomahu_HU
dc.subjectsurgeryhu_HU
dc.subjectTSH suppressionhu_HU
dc.subjectRAIhu_HU
dc.subjectconventional cytotoxic therapyhu_HU
dc.subjectEBRhu_HU
dc.subjectdedifferentiated thyroid cancerhu_HU
dc.subjecttyrosine kinase inhibitorhu_HU
dc.subjectRas pathwayhu_HU
dc.subjectMAPK pathwayhu_HU
dc.subjectmonoclonal antibodieshu_HU
dc.subjectBARFhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titlePharmacological Therapy of Differentiated Thyroid Cancerhu_HU
dc.title.translatedPharmacological Therapy of Differentiated Thyroid Cancerhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)